CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing new cancer therapies targeting the KRAS oncogene, which is frequently mutated in lung cancer. By exploring the vulnerabilities of RAS mutant cancer cells, the research aims to identify effective treatment strategies that could improve outcomes for patients.
Lung cancer is the most common type of malignant tumour worldwide and the leading cause of cancer-related death (335,000 deaths per year in Europe).
The KRAS oncogene is frequently activated by point mutation in human lung cancer and mutations in the RAS family oncogenes are responsible for driving some 20% of all human malignancies.
Most cell lines from RAS mutant tumours remain “oncogene addicted” to continued RAS function.
There is therefore a pressing need to develop cancer therapies that ta…
THE FRANCIS CRICK INSTITUTE LIMITED
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
